Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Impact · against what's priced in

Zhejiang Wenda Pharma provides a positive clinical catalyst with Phase II data showing a 30% ORR and a median OS of 9.33 months for NHWD-870 HCl in NUT carcinoma. While the BTD designation was previously known, the specific efficacy gains over the 6.7-month benchmark and the higher response rate in thoracic tumors provide new fundamental support for the asset's valuation.

Scored by the NIS engine · methodology.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

clinical trials▲106%
biotech

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Track these names every morning.

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Next reads from the same story arc

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Track these names every morning.

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3